Sickle Cell Data Show Value Of Novartis’s Recently Acquired SEG101
Executive Summary
Phase II SUSTAIN data presented at ASH show a statistically significant reduction in sickle cell pain crises for SEG101 (crizanlizumab), a potential blockbuster for Novartis, which recently said it will pay up to $665m for the antibody’s developer.
You may also be interested in...
Keeping Track: A Week Of Calm As Shutdown Drags On
The latest drug development news and highlights from our US FDA Performance Tracker.
Sickle Cell Innovators Required: Emmaus' Pending Approval Highlights Rare Disease Void
FDA approval is likely for Emmaus' sickle cell drug L-glutamine this summer, representing the first new product for the disease since 1998 – a decision FDA advisory committee panelists hope will spur more innovation.
Novartis Claims New Drugs, Pipeline Will Fuel Growth, Not M&A
Novartis sees itself engaging in only modest M&A activity to avoid over-paying for targets - and will rely on newly launched drugs and promising external targets to grow sales.